Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX PLUS D versus ZOMETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX PLUS D versus ZOMETA.
FOSAMAX PLUS D vs ZOMETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), thereby preventing the prenylation of small GTPase signaling proteins essential for osteoclast activity.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
4 mg IV over 15 minutes every 3-4 weeks for hypercalcemia of malignancy or bone metastases.
None Documented
None Documented
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Terminal elimination half-life is approximately 146 hours (6.1 days) due to prolonged release from bone; clinical context: supports monthly dosing for osteoporosis and quarterly for Paget's disease.
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Renal: 50-60% of the dose excreted unchanged in urine within 24 hours; terminal elimination involves slow release from bone with subsequent renal excretion; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Bisphosphonate
Bisphosphonate